非埃索诺菲尔性食道炎的药理管理 埃索诺菲尔性胃肠道疾病的药理管理
Evan S Dellon1, Sandeep K Gupta2
1Division of Gastroenterology and Hepatology, Department of Medicine, Center for Esophageal Diseases and Swallowing, University of North Carolina School of Medicine, 130 Mason Farm Road, Chapel Hill, NC 27599-7080, USA.
Immunology and allergy clinics of North America
|April 4, 2024
概括
对于eosinophilic胃肠道疾病 (EGIDs) 的药理疗法是有限的,但在不断发展. 皮质类固醇是一种常见的初始疗法,生物药物显示出有望针对这些罕见疾病的向治疗.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 对于非乙酸性食道炎 (EoE) 和其他乙酸性胃肠疾病 (EGID) 的药理疗法,数据有限.
- 目前对EGID的治疗主要是非标签的,需要进一步研究有效的治疗策略.
- 了解EGID的发病因子正在进步,指导着向治疗的开发.
研究的目的:
- 审查目前和新兴的药理疗法,以治疗埃索诺菲尔性胃肠道疾病 (EGIDs).
- 突出皮质类固醇,小分子和生物制剂在控制EGIDs中的作用.
- 确定EGID的潜在治疗点,其中许多与EoE共享.
主要方法:
- 对EGIDs的药理疗法现有研究的文献综述.
- 分析当前的治疗方法,包括皮质类固醇,小分子和生物药物.
- 基于EGID病原体的治疗点的识别.
主要成果:
- 皮质类固醇是一种主要的初始疗法,局部输送优于全身输送,以最大限度地减少副作用.
- 包括过敏药物和免疫抑制剂在内的各种小分子显示出EGID治疗的潜力.
- 生物药物越来越多地被使用和研究,为EGID提供了有前途的向治疗选择.
结论:
- 虽然EGID的药理选择有限,但包括皮质类固醇,小分子和生物制剂在内的一系列治疗方法被非标签地使用.
- 由于安全性,局部皮质类固醇是首选的初始管理.
- 生物药物代表了针对性EGID治疗的有希望的途径,已经确定了几种治疗点.
相关概念视频
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
78
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
78
01:26Peptic Ulcer Disease IV: Management
91
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
91
01:29Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
01:21Barrett Esophagus-II: Clinical Manifestations and Management
141
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
141
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
288
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
288
01:26Esophageal Strictures-II: Clinical Features and Management
69
Patients with esophageal strictures often experience a range of symptoms. Initially, they may have difficulty swallowing solid foods, which can progress to include liquids. Additional symptoms may involve chest pain or discomfort, regurgitating food and fluids, heartburn, unintentional weight loss, coughing or choking during meals, and hoarseness.
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
69